byiShook Opinion
Jul 22, 2025 - 15:45
Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma treatment. The post Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock appeared first on Investor's Business Daily.
Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma treatment.
The post Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock appeared first on Investor's Business Daily.